Skip to main content
Top
Published in: Rheumatology International 5/2014

01-05-2014 | Short Communication

The inflammatory circuitry of miR-149 as a pathological mechanism in osteoarthritis

Authors: Paolo Santini, Laura Politi, Pietro Dalla Vedova, Roberto Scandurra, Anna Scotto d’Abusco

Published in: Rheumatology International | Issue 5/2014

Login to get access

Abstract

Osteoarthritis (OA) is a multifactorial degenerative pathology, whose progression is exacerbated by pro-inflammatory cytokines signaling. Among the changes triggered in chondrocytes during inflammation, modified expression of tiny epigenetic regulators as microRNAs was shown having deleterious implications for articular cartilage. Aim of the present study was to identify differentially expressed microRNAs in human OA cartilage and to determine their relevance to pathological progression. An OA model based on inflammatory stimulation of a chondrocytic human cell line was used to analyze microRNAs deregulation, and results revealed miR-149 severely down-regulated by IL1β and TNFα. Real-time PCR analysis of miR-149 was exerted also in human primary chondrocytes isolated from cartilage of OA donors and postmortem from subjects with no known history of OA, confirming down-regulation in osteoarthritis. Moving on a functional study, miR-149 regulatory effect on tumor necrosis factor alpha (TNFα), interleukin 1 beta (IL1β) and interleukin 6 (IL6) 3′UTRs was evaluated by luciferase assays, and chondrocytes production of TNFα upon miR-149 transfection was measured by enzyme-linked immuno sorbent assay. We found that miR-149 is down-regulated in OA chondrocytes, and this decrease seems to be correlated to increased expression of pro-inflammatory cytokines such as TNFα, IL1β and IL6. OA is a multifactorial disease and we think that our results give new insights for understanding the complex mechanisms of osteoarthritic pathogenesis.
Literature
1.
go back to reference Arden N, Nevitt MC (2006) Osteoarthritis: epidemiology. Best Pract Res Cl Rh 20(1):3–25CrossRef Arden N, Nevitt MC (2006) Osteoarthritis: epidemiology. Best Pract Res Cl Rh 20(1):3–25CrossRef
5.
7.
go back to reference Jones SW, Watkins G, Le Good N et al (2009) The identification of differentially expressed microRNA in osteoarthritic tissue that modulate the production of TNFa and MMP13. Osteoarthr Cartilage 17(4):464–472. doi:10.1016/j.joca.2008.09.012 CrossRef Jones SW, Watkins G, Le Good N et al (2009) The identification of differentially expressed microRNA in osteoarthritic tissue that modulate the production of TNFa and MMP13. Osteoarthr Cartilage 17(4):464–472. doi:10.​1016/​j.​joca.​2008.​09.​012 CrossRef
10.
14.
go back to reference Nomura E, Inoue M (2004) Cartilage lesions of the patellae in recurrent patellar dislocation. Am J Sport Med 32:498–502CrossRef Nomura E, Inoue M (2004) Cartilage lesions of the patellae in recurrent patellar dislocation. Am J Sport Med 32:498–502CrossRef
15.
go back to reference Scotto d’Abusco A, Calamia V, Cicione C, Grigolo B, Politi L, Scandurra R (2007) Glucosamine affects intracellular signalling through inhibition of mitogen-activated protein kinase phosphorylation in human chondrocytes. Arthritis Res Ther 9:R104PubMedCentralCrossRef Scotto d’Abusco A, Calamia V, Cicione C, Grigolo B, Politi L, Scandurra R (2007) Glucosamine affects intracellular signalling through inhibition of mitogen-activated protein kinase phosphorylation in human chondrocytes. Arthritis Res Ther 9:R104PubMedCentralCrossRef
16.
go back to reference Díaz-Prado S, Cicione C, Muiños-López E, Hermida-Gómez T, Oreiro N, Fernández-López C, Blanco FJ (2012) Characterization of microRNA expression profiles in normal and osteoarthritic human chondrocytes. BMC Musculoskelet Disord 13:144PubMedCentralPubMedCrossRef Díaz-Prado S, Cicione C, Muiños-López E, Hermida-Gómez T, Oreiro N, Fernández-López C, Blanco FJ (2012) Characterization of microRNA expression profiles in normal and osteoarthritic human chondrocytes. BMC Musculoskelet Disord 13:144PubMedCentralPubMedCrossRef
18.
go back to reference Wang Y, Zheng X, Zhang Z, Zhou J, Zhao G, Yang J et al (2012) MicroRNA-149 inhibits proliferation and cell cycle progression through the targeting of ZBTB2 in human gastric cancer. PLoS ONE 7(10):e41693PubMedCentralPubMedCrossRef Wang Y, Zheng X, Zhang Z, Zhou J, Zhao G, Yang J et al (2012) MicroRNA-149 inhibits proliferation and cell cycle progression through the targeting of ZBTB2 in human gastric cancer. PLoS ONE 7(10):e41693PubMedCentralPubMedCrossRef
19.
go back to reference Guglielmelli P, Tozzi L, Pancrazzi A, Bogani C, Antonioli E, Ponziani V et al (2007) MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol 35:1708–1718PubMedCrossRef Guglielmelli P, Tozzi L, Pancrazzi A, Bogani C, Antonioli E, Ponziani V et al (2007) MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol 35:1708–1718PubMedCrossRef
Metadata
Title
The inflammatory circuitry of miR-149 as a pathological mechanism in osteoarthritis
Authors
Paolo Santini
Laura Politi
Pietro Dalla Vedova
Roberto Scandurra
Anna Scotto d’Abusco
Publication date
01-05-2014
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 5/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2754-8

Other articles of this Issue 5/2014

Rheumatology International 5/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.